Does the media favor STRO or RXRX?

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Sutro Biopharma. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.22 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, STRO or ANAB?

AnaptysBio has higher revenue and earnings than Sutro Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $99.61M 3.37 -$191.09M -$11.04 N/A AnaptysBio $234.60M 7.20 -$13.23M -$1.08 N/A

Is STRO or ANAB more profitable?

AnaptysBio has a net margin of -11.53% compared to Sutro Biopharma's net margin of -154.21%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -154.21% N/A -69.20% AnaptysBio -11.53% N/A -7.75%

Does the media refer more to STRO or ANAB?

In the previous week, Sutro Biopharma had 2 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Sutro Biopharma and 3 mentions for AnaptysBio. Sutro Biopharma's average media sentiment score of 1.87 beat AnaptysBio's score of 0.94 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or STRO?

In the previous week, Sarepta Therapeutics had 19 more articles in the media than Sutro Biopharma. MarketBeat recorded 24 mentions for Sarepta Therapeutics and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Sarepta Therapeutics' score of 0.69 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SEPN or STRO?

In the previous week, Septerna had 11 more articles in the media than Sutro Biopharma. MarketBeat recorded 16 mentions for Septerna and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Septerna's score of 0.56 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, XNCR or STRO?

Xencor has higher revenue and earnings than Sutro Biopharma. Xencor is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $104.97M 16.34 -$91.92M -$2.17 N/A Sutro Biopharma $99.61M 3.37 -$191.09M -$11.04 N/A

Is XNCR or STRO more profitable?

Sutro Biopharma has a net margin of -154.21% compared to Xencor's net margin of -155.59%. Sutro Biopharma's return on equity of 0.00% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% Sutro Biopharma -154.21% N/A -69.20%

Does the media refer more to XNCR or STRO?

In the previous week, Xencor had 14 more articles in the media than Sutro Biopharma. MarketBeat recorded 19 mentions for Xencor and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Xencor's score of 0.58 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 4 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Sutro Biopharma (STRO) Competitors

$20.24 -4.80 (-19.17%)

As of 02:51 PM Eastern

Compare

STRO vs. RXRX, ANAB, SRPT, SEPN, and XNCR

Should you buy Sutro Biopharma stock or one of its competitors? Sutro Biopharma's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), AnaptysBio (ANAB), Sarepta Therapeutics (SRPT), Septerna (SEPN), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Sutro Biopharma (NASDAQ:STRO) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Sutro Biopharma has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Sutro Biopharma has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$99.61M	3.37	-$191.09M	-$11.04	N/A
Recursion Pharmaceuticals	$53.94M	32.42	-$644.76M	-$1.04	N/A

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Sutro Biopharma. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.22 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sutro Biopharma has a net margin of -154.21% compared to Recursion Pharmaceuticals' net margin of -945.94%. Sutro Biopharma's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sutro Biopharma presently has a consensus price target of $52.00, suggesting a potential upside of 156.92%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 145.45%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Sutro Biopharma is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Sutro Biopharma beats Recursion Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to AnaptysBio?

Sutro Biopharma (NASDAQ:STRO) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

AnaptysBio has higher revenue and earnings than Sutro Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$99.61M	3.37	-$191.09M	-$11.04	N/A
AnaptysBio	$234.60M	7.20	-$13.23M	-$1.08	N/A

Sutro Biopharma has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

97.0% of Sutro Biopharma shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sutro Biopharma currently has a consensus target price of $52.00, indicating a potential upside of 156.92%. AnaptysBio has a consensus target price of $82.00, indicating a potential upside of 43.83%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sutro Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sutro Biopharma had 2 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Sutro Biopharma and 3 mentions for AnaptysBio. Sutro Biopharma's average media sentiment score of 1.87 beat AnaptysBio's score of 0.94 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has a net margin of -11.53% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

Sutro Biopharma beats AnaptysBio on 8 of the 15 factors compared between the two stocks.

How does Sutro Biopharma compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Sarepta Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Sutro Biopharma has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.89	-$713.41M	-$2.90	N/A
Sutro Biopharma	$99.61M	3.37	-$191.09M	-$11.04	N/A

In the previous week, Sarepta Therapeutics had 19 more articles in the media than Sutro Biopharma. MarketBeat recorded 24 mentions for Sarepta Therapeutics and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Sarepta Therapeutics' score of 0.69 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	7 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sarepta Therapeutics has a net margin of -13.48% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Sutro Biopharma	-154.21%	N/A	-69.20%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sarepta Therapeutics presently has a consensus target price of $25.06, indicating a potential upside of 36.04%. Sutro Biopharma has a consensus target price of $52.00, indicating a potential upside of 156.92%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Sutro Biopharma beats Sarepta Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Septerna?

Septerna (NASDAQ:SEPN) and Sutro Biopharma (NASDAQ:STRO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Septerna had 11 more articles in the media than Sutro Biopharma. MarketBeat recorded 16 mentions for Septerna and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Septerna's score of 0.56 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.0% of Sutro Biopharma shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Septerna currently has a consensus price target of $49.22, suggesting a potential upside of 2.42%. Sutro Biopharma has a consensus price target of $52.00, suggesting a potential upside of 156.92%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Septerna has higher earnings, but lower revenue than Sutro Biopharma. Septerna is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	21.91	-$48.88M	-$0.54	N/A
Sutro Biopharma	$99.61M	3.37	-$191.09M	-$11.04	N/A

Septerna has a net margin of -24.51% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.59%	-6.22%
Sutro Biopharma	-154.21%	N/A	-69.20%

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Summary

Sutro Biopharma beats Septerna on 9 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Xencor?

Xencor (NASDAQ:XNCR) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Xencor has higher revenue and earnings than Sutro Biopharma. Xencor is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$104.97M	16.34	-$91.92M	-$2.17	N/A
Sutro Biopharma	$99.61M	3.37	-$191.09M	-$11.04	N/A

97.0% of Sutro Biopharma shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sutro Biopharma has a net margin of -154.21% compared to Xencor's net margin of -155.59%. Sutro Biopharma's return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Sutro Biopharma	-154.21%	N/A	-69.20%

Xencor currently has a consensus target price of $24.86, suggesting a potential upside of 7.75%. Sutro Biopharma has a consensus target price of $52.00, suggesting a potential upside of 156.92%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Xencor has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

In the previous week, Xencor had 14 more articles in the media than Sutro Biopharma. MarketBeat recorded 19 mentions for Xencor and 5 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Xencor's score of 0.58 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	4 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Sutro Biopharma beats Xencor on 10 of the 17 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$335.38M	$3.73B	$7.05B	$12.97B
Dividend Yield	N/A	3.76%	2.58%	10.34%
P/E Ratio	-1.83	10.41	268.79	25.29
Price / Sales	3.37	1,243.53	583.20	76.10
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	-1.31	17.86	13.14	6.23
Net Income	-$191.09M	-$13.23M	$3.45B	$347.40M
7 Day Performance	-19.36%	3.40%	1.95%	1.44%
1 Month Performance	-31.92%	-0.82%	-0.29%	-0.49%
1 Year Performance	158.26%	60.32%	70.54%	20.99%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	3.2044 of 5 stars	$20.24 -19.2%	$52.00 +156.9%	+224.1%	$335.38M	$99.61M	N/A	240	News Coverage Positive News Earnings Report Gap Down High Trading Volume
RXRX Recursion Pharmaceuticals	1.942 of 5 stars	$3.18 +6.0%	$8.10 +154.7%	-36.7%	$1.59B	$74.68M	N/A	400	Earnings Report Options Volume
ANAB AnaptysBio	2.6977 of 5 stars	$53.66 +0.6%	$82.00 +52.8%	+189.4%	$1.58B	$234.60M	N/A	100
SRPT Sarepta Therapeutics	3.5398 of 5 stars	$15.88 +6.9%	$24.72 +55.7%	+1.6%	$1.57B	$2.18B	N/A	1,372
SEPN Septerna	1.2027 of 5 stars	$34.98 +1.5%	$45.89 +31.2%	+315.7%	$1.55B	$45.95M	N/A	N/A	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. RXRX, ANAB, SRPT, SEPN, and XNCR

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Summary

How does Sutro Biopharma compare to AnaptysBio?

Summary

How does Sutro Biopharma compare to Sarepta Therapeutics?

Summary

How does Sutro Biopharma compare to Septerna?

Summary

How does Sutro Biopharma compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. RXRX, ANAB, SRPT, SEPN, and XNCR

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Which has more volatility & risk, STRO or RXRX?

Which has preferable earnings & valuation, STRO or RXRX?

Does the media favor STRO or RXRX?

Is STRO or RXRX more profitable?

Do insiders & institutionals have more ownership in STRO or RXRX?

Do analysts rate STRO or RXRX?

Summary

How does Sutro Biopharma compare to AnaptysBio?

Which has higher earnings and valuation, STRO or ANAB?

Which has more volatility & risk, STRO or ANAB?

Do insiders and institutionals believe in STRO or ANAB?

Do analysts recommend STRO or ANAB?

Does the media refer more to STRO or ANAB?

Is STRO or ANAB more profitable?

Summary

How does Sutro Biopharma compare to Sarepta Therapeutics?

Which has more volatility and risk, SRPT or STRO?

Which has preferable valuation and earnings, SRPT or STRO?

Does the media prefer SRPT or STRO?

Is SRPT or STRO more profitable?

Do institutionals & insiders believe in SRPT or STRO?

Do analysts prefer SRPT or STRO?

Summary

How does Sutro Biopharma compare to Septerna?

Does the media favor SEPN or STRO?

Do insiders and institutionals hold more shares of SEPN or STRO?

Do analysts rate SEPN or STRO?

Which has better valuation & earnings, SEPN or STRO?

Is SEPN or STRO more profitable?

Which has more risk and volatility, SEPN or STRO?

Summary

How does Sutro Biopharma compare to Xencor?

Which has better valuation & earnings, XNCR or STRO?

Do insiders & institutionals have more ownership in XNCR or STRO?

Is XNCR or STRO more profitable?

Do analysts recommend XNCR or STRO?

Which has more risk & volatility, XNCR or STRO?

Does the media refer more to XNCR or STRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools